<?xml version="1.0" encoding="UTF-8"?>
<p>There could be an insurance-like gain if the program is to develop a portfolio of vaccines against many different types of disease, so that the probability that some of those vaccines are going to be of benefit is high. The important point in this case is that the value of the program is not based on the worst case scenario in which every vaccine is needed, but instead is based on the average or expected prospective usage of each vaccine, potentially adjusted upwards to reflect peopleâ€™s willingness to pay to avoid risk.</p>
